drugset
drugset / Trial / NCT05525546

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

NCT05525546 ↗

Phase 1 Completed 82 enrolled University of Maryland, Baltimore
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, placebo-controlled interventional study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.

Timeline

Start
2022-08-15
Primary completion
2023-06-12
Completion
2023-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Trivalent Salmonella Conjugate Vaccine Vaccine 12.5 ug Intramuscular
Subject Trivalent Salmonella Conjugate Vaccine Vaccine 25 ug Intramuscular

Indications

No indication recorded.